The latest: another human umbilical cord-filling stem cell IND to receive the treatment of the medical wheat mammoth explosion.

This article is original and welcome to share. The reprint must be authorized. June 6, 2020 / emedclub news / - - according to the official website of the drug evaluation center (CDE) of the State Drug Administration, the application for clinical trial of a new drug of human umbilical cord mesenchymal stem cells for injection by Shenzhen Beike Biotechnology Co., Ltd. was accepted on June 5.it is reported that this new stem cell drug is the first stem cell product for the treatment of refractory systemic lupus erythematosus in China.novel coronavirus clinical research project of Shenzhenthird, the only one designated by Shenzhen City, has been awarded the new research project of Guangdong provincial science and technology department in 2020 to prevent and control the new coronavirus.Beike biology has always adhered to the R & D and innovation in the field of cells, and actively participated in the clinical research of mesenchymal stem cells in refractory diseases. The "key technical innovation and clinical application of allogeneic mesenchymal stem cells in the treatment of refractory lupus erythematosus" jointly carried out by the company and Nanjing Gulou Hospital won the honor of 2019 National Technological Invention Award.recommended reading: the list of winners of the national science and Technology Award in 2019 was announced, and the project of allogeneic mesenchymal stem cells of sun Lingyun team won the second prize of national technological invention. According to the domestic regulatory approval, the potential of umbilical cord mesenchymal stem cells can be seen from the perspective of domestic regulatory approval. The drug registration management measures (Revised Version) released in 2017 clearly pointed out that cell therapy products can be registered and marketed according to drugs Following the promulgation of the technical guidelines for the research and evaluation of cell therapy products (Trial Implementation), the standard for the application of cell therapy as a drug was further clarified.since June 2018, 13 ind applications for new stem cell drugs have been officially accepted by the National Drug Evaluation Center (CDE). In addition to regen001 cell autotransfusion preparation independently developed by Jiangxi Xianhe Medical Technology Co., Ltd., the other 12 stem cells are mesenchymal stem cells.up to now, eight new stem cell drugs, ind, have been approved by clinical practice in China. They are mesenchymal stem cells derived from placenta, umbilical cord and allogeneic / autologous fat. Four of them were approved this year.in addition, among the 13 new stem cell drugs accepted by CDE, six are human umbilical cord mesenchymal stem cells, and four of them have obtained clinical tacit permission. Moreover, it is not difficult to find that three of the four new stem cell drugs approved for clinical use in less than half a year are umbilical cord mesenchymal stem cells.its potential is worth looking forward to! Mesenchymal stem cells (MSCs) are a very special type of adult stem cell family. They can differentiate into a variety of tissue cells, such as bone cells, chondrocytes, muscle cells, adipocytes and nerve cells.in addition to repairing the damaged tissues, the therapeutic effect of MSCs is mainly attributed to its immunomodulatory function under the regulation of inflammatory environment and its powerful paracrine effect, which is expected to be used in the treatment of a wide range of degenerative and inflammatory diseases.human umbilical cord is an important source of mesenchymal stem cells.unlike bone marrow stem cells, human umbilical cord mesenchymal stem cells (hUCMSCs) have the characteristics of painless collection and faster self-renewal.different derivatization schemes may provide different numbers and populations of stem cells.compared with embryonic stem cells, hUCMSCs have no ethical controversy.therefore, more and more researchers pay attention to this kind of cells.novel coronavirus pneumonia is also worthy of mention. It is based on the immunomodulatory function of mesenchymal stem cells, and it also has great potential in the exploration of the new crown pneumonia treatment. The novel coronavirus pneumonia is a new strategy for the treatment of severe acute lung cancer. The new clinical trial of stem cell therapy is a new strategy for the treatment of severe acute respiratory syndrome. The clinical projects of these companies are worthy of attention. The new medicine therapy of Mai's new medicine is supported by three positive results. The stem cell therapy of Mesoblast, a leading Mesoblast of regenerative medicine, is expected to be approved for listing. The is a new strategy for treating severe cases of new crown pneumonia. The new clinical trial of is a new strategy. From July 19 to 21, 2020, we focused on the four hot biomedical fields including tumor immunity, new antibodies, stem cell regeneration medicine and gene therapy At the biopharmaceutical innovation technology conference, the second international stem cell industry transformation leaders summit will be one of the sub venues, and many famous experts and scholars will be invited to share the research and development progress and the latest relevant policies in the field of stem cells. at that time, we will gather in Nanjing International Youth Culture Center of China to share this academic feast! Click the picture above to view the agenda of the conference